Here are the 10-K annual reports from Boston Scientific Corporation (BSX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSX filings page.
Boston Scientific Corporation provides an overview of its global medical device business, strategy and key transactions in its annual report for the year ended December 31, 2025. The company highlights a definitive agreement to acquire Penumbra for $14.500 billion, funded with approximately $11.000 billion of cash and new debt and the balance in stock.
Boston Scientific reports an aggregate market value of common stock held by non‑affiliates of about $158.7 billion based on a $107.41 share price on June 30, 2025, and 1,483,885,456 shares outstanding as of January 30, 2026. Total debt was $11.436 billion as of December 31, 2025. The company employed roughly 59,000 people worldwide at year‑end 2025, with 36 percent of net sales generated outside the U.S.
The report details two completed 2025 acquisitions—Bolt Medical and SoniVie—to expand intravascular and hypertension technologies, and explains a 2023 restructuring program expected to generate annual pre‑tax savings of $350 million to $400 million from total charges of $700 million to $800 million. Extensive risk disclosures cover competition, pricing pressure, regulation, cybersecurity, supply chain, climate and human‑capital challenges.